Warfarin use among patients with atrial fibrillation

Stroke

Volumn 28, Issue 12, 1997, Pages 2382-2389

  Brass, Lawrence M ^a,b,c,d   Krumholz, Harlan M ^a,c,d   Scinto, Jeanne M ^d   Radford, Martha ^d,e  

^a YALE NEW HAVEN HOSPITAL   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d School of Medicine ^*  (United States)

^e UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Anticoagulants; Atrial fibrillation; Stroke prevention; Warfarin

Indexed keywords

WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CARDIOVASCULAR DISEASE; FEMALE; HEART ATRIUM FIBRILLATION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; POPULATION RESEARCH; PRIORITY JOURNAL; SINUS RHYTHM; STROKE;

EID: 0031470274     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.28.12.2382     Document Type: Article

References (59)

1. Hennen J, Krumholz HM, Radford MJ. Twenty most frequent DRG groups among Medicare in patients age 65 or older in Connecticut hospitals, fiscal years 1991, 1992, and 1993. CT Med. 1995; 59:11-15.
2. Hennen J, Krumholz HM, Radford MJ, Meehan TP. Readmission rates, 30 days and 365 days postdischarge, among the 20 most frequent DRG groups, Medicare in patients age 65 or older in Connecticut hospitals, fiscal years 1991, 1992, and 1993. CT Med. 1995;59:263-270.
3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
4. Kay R. Wong KS, Yu YL, Chan YW, Tsoi TH, Ahuja AT, Chan FL, Fong KY, Law CB, Wong A, Woo J. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med. 1995;333: 1588-1593.
5. Wolf PA. Contributions of epidemiology to the prevention of stroke. Circulation. 1993;88:2471-2478.
6. Barnett HJM, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med. 1995;332:238-248.
7. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med. 1995;155:469-473.
8. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as in independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22:983-988.
9. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiological assessment of chronic atrial fibrillation and the risk of stroke: the Framingham Study. Neurology. 1978;28:973-977.
10. Jørgensen HS, Nakayama H, Reith J, Raasschou HO, Olsen TS. Acute stroke with atrial fibrillation: the Copenhagen Stroke Study. Stroke. 1996;10:1765-1769.
11. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D'Agostino RB. Stroke severity in atrial fibrillation: the Framingham Study. Stroke. 1996;27:1760-1764.
12. Fisher CM. Reducing the risks of cerebral embolism. Geriatrics. 1979;34:59-66.
13. EAFT (European Atrial Fibrillation Trial) Study Group. European Atrial Fibrillation Trial: secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-1262.
14. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest. 1995;108: 352S-359S.
15. Connolly SJ. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. JAm Coll Cardiol. 1991;18:349-355.
16. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, for the Veterans Affairs Stroke Prevention in Non-rheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327:1406-1412.
17. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation (SPAF) Study: final results. Circulation. 1991;84:527-539.
18. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-691.
19. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet. 1989;1:175-179.
20. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-1511.
21. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994; 154:1449-1457.
22. Gustafsson C, Asplund K, Britton M, Norrving B, Olsson B, Marke LA. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ. 1992;305:1457-1460.
23. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274: 1839-1845.
24. Laupacis A, Albers G, Dunn M, Feinberg W. Antithrombotic therapy in atrial fibrillation. Chest. 1992;102(suppl 4):426S-433S.
25. Matchar DB, McCroy DC, Barnett HJM, Feussner JR. Guidelines for medical treatment for stroke prevention. Ann Intern Med. 1994; 121:54-55.
26. Albers GW. Atrial fibrillation and stroke: three new studies, three remaining questions. Arch Intern Med. 1994;154:1443-1448.
27. Gurwitz JH, Gore JM, Goldberg RJ, Rubison M, Chandra N, Rogers WJ. Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction. Ann Intern Med. 1996;124:283-291.
28. Krumholz HM, Radford MJ, Ellerbeck E, Hennen J, Meehan TP, Petrillo M, Wang Y, Kresowik TF, Jencks SF. Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries: patterns of use and outcomes. Circulation. 1995;92: 2841-2847.
29. Krumholz HM, Radford MJ, Ellberbeck E, Hennen J, Meehan TP, Petrillo M, Wang Y, Jencks SF. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med. 1996;124:292-298.
30. McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett ELC. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med. 1995;155:277-281.
31. Kutner M, Nixon G, Silverstone F. Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med. 1991;151: 1950-1953.
32. Brodsky MA, Chun JG, Podrid PJ, Douban S, Allen BJ, Cygan R. Regional attitudes of generalists, specialists, and subspecialists about management of atrial fibrillation. Arch Intern Med. 1996;156: 2553-2562.
33. Schlicht JR, Davis RC, Naqi K, Cooper W, Rao V. Physician practices regarding anticoagulation and cardioversion of atrial fibrillation. Arch Intern Med. 1996;156:290-294.
34. Albers GW, Yim JM, Belew KM, Bittar N, Hattemer CR, Phillips BG, Kemp S, Hall EA, Morton DJ, Vlasses PH. Status of antithrombotic therapy for patients with atrial fibrillation in university patients. Arch Intern Med. 1996;156:2311-2316.
35. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med. 1996;156:2537-2541.
36. Munschauer FE, Priore RL, Hens M, Castilone A. Thromboembolism prophylaxis in chronic atrial fibrillation: practice patterns in community and tertiary-care hospitals. Stroke. 1997;28:72-76.
37. Brass LM, Radford MJ, The use of warfarin among Medicare patients with atrial fibrillation following hospitalization for ischemic stroke. Circulation. 1996:94(suppl I):I-34. Abstract.
38. Ellerbeck EF, Jencks SF, Radford MJ, Kresowik TF, Craig AS, Gold JA, Krumholz HM, Vogel RA. Quality of care for Medicare patients with acute myocardial infarction: a four-state pilot project from the cooperative cardiovascular project. JAMA. 1995;273: 1509-1514.
39. Furberg CD, Psaty BM, Gardin JM, Smith VE, Rautanarju PM. Prevalence of atrial fibrillation in elderly subjects (The Cardiovascular Health Study). Am J Cardiol. 1994;74:238-241.
40. Laupacis A. Anticoagulants for atrial fibrillation. Lancet. 1993;342: 1251-1252.
41. Lamas GA, Pfeffer MA, Hamm P, Wertheimer J. Rouleau JL, Braunwald E. Do the results of randomized trials of cardiovascular drugs influence medical practice? N Engl J Med. 1992;327:241-247.
42. Col NF, McLaughlin TJ, Soumerai SB, Hosmer DW Jr, Yarzebski J, Gurwitz JH. Gore JM, Goldberg RJ. The impact of clinical trials on the use of medications for acute myocardial infarction. Arch Inem Med. 1996;156:54-60.
43. Ketley D, Woods KL. Impact of clinical trials on clinical practice: example of thrombolysis for acute myocardial infarction. Lancet. 1993;342:891-894.
44. The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med. 1996;156:409-416.
45. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S, on behalf of the Italian Study on Complications of Oral Anticoagulant Therapy. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet. 1996;348:423-428.
46. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH, for the National Consortium of Anticoagulation Clinics. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med. 1996;124:970-979.
47. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996; 335:540-546.
48. Connolly S, for the Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:1509. Letter.
49. Hart RG, Halperin JL. Atrial fibrillation and stroke: revisiting the dilemmas. Stroke. 1994;25:1337-1341.
50. Sudlow CM, Rodgers H, Kenny RA, Thomson RG. Service provision and use of anticoagulants in atrial fibrillation. BMJ. 1995; 311:558-561.
51. Man-Son-Hing M. Laupacis A, O-Conner A, Wells G, Lemelin J, Wood W, Dermer M. Warfarin for atrial fibrillation: the patient's perspective. Arch Intern Med. 1996;156:1841-1848.
52. Sweeney KG, Pereira Gray DJ, Steele RJF, Evans PH. Commentary: caution needed in introducing warfarin treatment. BMJ. 1995;311:560-561.
53. Kase CS, Robinson RK, Stein RW, DeWitt LD, Hier DB, Harp DL, Williams JP, Caplan LR, Mohr JP. Anticoagulant-related intracerebral hemorrhage, Neurology. 1985;35:943-948.
54. Wintzen AR, de Jonge H, Loeliger EA, Bots GTAM. The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study. Ann Neurol. 1984;16:553-558.
55. Ng VL, Levin J, Corash L, Gottfried EL. Failure of the international normalized ratio to generate consistent results within a local medical community. Am J Clin Pathol. 1993;99:689-694.
56. Koepke JA. Is the international normalized ratio also 'valid' for prothrombin times measured in patients not receiving oral anticoagulants? Arch Pathol Lab Med 1994;118:1181-1182.
57. Hirsh J, Poller L. The international normalized ratio: a guide to understanding and correcting its problems. Arch Intern Med. 1994; 154:282-289.
58. Becker DM, Humphries JE, Walker FB IV, DeMong LK, Boop JS, Acker MN. Standardizing the prothrombin time. Arch Pathol Lab Med. 1993;117:602-605.
59. Ts'ao C, Swedlund J, Neofotistos D. Implications of use of low international sensitivity index thromboplastins in prothrombin time testing. Arch Pathol Lab Med. 1994;118:1183-1187.